May 28, 2013
JAMS President Fumimaro Takaku (center), Others Meet Press in Tokyo The Japanese Association of Medical Sciences (JAMS) said on May 24 that some papers on a key investigator-led study for Novartis Pharma’s angiotensin receptor blocker Diovan (valsartan) violated its guidelines,...read more